Maarten van der Doelen

Actinium-225 labeled PSMA radioligand therapy in mCRPC patients

2

Supplementary figure 2. Immunohistochemistry analysis of PSMA expression. PSMA staining intensity was assessed semiquantitatively by assignment of the H-score on a scale from 0 to 300, defined as the product of the percentage of the immunopositive tumor cells (0% to 100%) and the staining intensity (0 = negative; 1+ = weak; 2+ = moderate; 3+ = intense). A. Staining intensity 0. Negative PSMA staining. Prostate needle biopsy. ID 05. B. Staining intensity 1. Weak staining of granules and cytoplasm. Bone metastasis needle biopsy. ID 01. C. Staining intensity 2. Moderate staining of cytoplasm; the cell nucleus and granules are visible. Bone metastasis needle biopsy. ID 01. D. Staining intensity 3. Intense homogeneous staining of cytoplasm; the cell nucleus is not visible. Lymph node metastasis needle biopsy. ID 07. Magnification 20x. Staining with anti-PSMA with 7E11 antibody, immunoperoxidase with hematoxylin counterstain.

51